At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 23 enrolled
Drug / intervention
Nivolumab +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Non-comparative Neoadjuvant Phase II Study in Patients With ER+/HER2- Breast Cancer >= 2 cm With Safety Run-in, Assessing Nivolumab + Palbociclib + Anastrozole
In Brief
A Phase 2 clinical trial evaluating Nivolumab, Anastrozole, and 1 other intervention for Breast Cancer and Cancer. Completed, enrolled 23 participants across 36 sites in 8 countries.
Detailed Summary
A randomized multi-arm study evaluating the safety and efficacy of palbociclib and anastrozole with or without nivolumab in participants with ER+/HER2- breast cancer
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer, Cancer
CountriesAustralia, Belgium, Canada, France, Germany, Puerto Rico, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedSep 2019
Enrollment StartOct 2019
Primary CompletionJul 2021
TodayJul 2026
First PostedSep 3, 2019
Enrollment StartOct 18, 2019
Primary CompletionJul 27, 2021
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 6.8 years ago
Interventions
Nivolumabbiological
Specified Dose on Specified Days
Anastrozoledrug
Specified Dose on Specified Days
Palbociclibdrug
Specified Dose on Specified Days